Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement BrainStorm Cell Therapeutics Inc. shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced its voluntary delisting from the Nasdaq Capital Market.
BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial.
Which stocks are moving after the closing bell on Thursday? Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
What's going on in today's pre-market session Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.
Gapping stocks in Monday's session Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.
These stocks are moving in today's pre-market session Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
BCLI Stock Earnings: Brainstorm Cell Misses EPS for Q2 2024 BCLI stock results show that Brainstorm Cell missed analyst estimates for earnings per share the second quarter of 2024.
